Related references
Note: Only part of the references are listed.Design and in Vitro Characterization of Tricyclic Benzodiazepine Derivatives as Potent and Selective Antileukemic Agents
Adam Mieczkowski et al.
CHEMISTRY & BIODIVERSITY (2021)
Unsymmetrically Substituted Dibenzo[b,f][1,5]-diazocine-6,12(5H,11H)dione-A Convenient Scaffold for Bioactive Molecule Design
Bartosz Bieszczad et al.
MOLECULES (2020)
Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs
Bartosz Bieszczad et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Unsymmetrically-Substituted 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-dione Scaffold-A Useful Tool for Bioactive Molecules Design
Bartosz Bieszczad et al.
MOLECULES (2020)
Influence of halogen size on the supramolecular and energy landscape of the THF solvates of the halogen derivatives of dianthranilide
Bartosz Bieszczad et al.
CRYSTENGCOMM (2020)
Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetyicholinesterase (AChE) and Phosphodiesterase 5 (PDE5)
Wei Ni et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Novel (S)-1,3,4,12a-tetrahydropyrazino[2,1-c][1,4]benzodiazepine-6,12 (2H,11H)-dione derivatives: Selective inhibition of MV-4-11 biphenotypic B myelomonocytic leukemia cells' growth is accompanied by reactive oxygen species overproduction and apoptosis
Adam Mieczkowski et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
A review of synthetic phosphodiesterase type 5 inhibitors (PDE-5i) found as adulterants in dietary supplements
Chee-Leong Kee et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease
Fei Mao et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents
Pan Pantziarka et al.
ECANCERMEDICALSCIENCE (2018)
Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis
Binbin Gong et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2017)
Structural Diversity and Biological Activities of the Cyclodipeptides from Fungi
Xiaohan Wang et al.
MOLECULES (2017)
Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses
Zhufeng Peng et al.
UROLOGIA INTERNATIONALIS (2017)
Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
Jessica C. Hassel et al.
ONCOIMMUNOLOGY (2017)
(S)-2-(4-Chlorobenzoyl)-1,2,3,4-tetrahydrobenzo[e]pyrazino[1,2-a][1,4]diazepine-6,12(11H,12aH)-dione-Synthesis and Crystallographic Studies
Adam Mieczkowski et al.
MOLBANK (2017)
Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets
Grona Bajraktari et al.
BIOCHEMICAL PHARMACOLOGY (2017)
The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma
Traci R. Tuttle et al.
CANCER LETTERS (2016)
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
Eugenio Ventimiglia et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
Ahmed K. Elhady et al.
SCIENTIA PHARMACEUTICA (2016)
PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types
Laurence Booth et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model
Rong Wang et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells
Marialuisa Sponziello et al.
ENDOCRINE (2015)
Tadalafil - a therapeutic option in the management of BPH-LUTS
C. C. Carson et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: Analytical techniques and challenges
Dhavalkumar Narendrabhai Patel et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Role of inorganic nitrate and nitrite in driving nitric oxide-GMP-mediated inhibition of platelet aggregation in vitro and in vivo
G. L. Apostoli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Developments around the bioactive diketopiperazines: a patent review
Yi Wang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia
Matthew A. Cantrell et al.
PHARMACOTHERAPY (2013)
2,5-Diketopiperazines: Synthesis, Reactions, Medicinal Chemistry, and Bioactive Natural Products
Alan D. Borthwick
CHEMICAL REVIEWS (2012)
Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives
Nermin S. Ahmed et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Tadalafil for the treatment of pulmonary arterial hypertension
Maria Klara Frey et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Design, Synthesis and Structure-Activity Relationship of Functionalized Tetrahydro-β-carboline Derivatives as Novel PDE5 Inhibitors
Nermin S. Ahmed et al.
ARCHIV DER PHARMAZIE (2011)
Anti-platelet therapy: phosphodiesterase inhibitors
Paolo Gresele et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension
Sally A. Arif et al.
CLINICAL THERAPEUTICS (2011)
Drug to Genome to Drug: Discovery of New Antiplasmodial Compounds
Terence B. Beghyn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
Pei-Rong Ding et al.
PLOS ONE (2011)
Tadalafil for the treatment of pulmonary arterial hypertension
James R. Klinger
EXPERT REVIEW OF RESPIRATORY MEDICINE (2011)
Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective
Ashraf H. Abadi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Tadalafil for the treatment of pulmonary arterial hypertension
Erika B. Rosenzweig
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect
Saisudha Koka et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
A Traceless, Solid-Supported Synthesis of beta-Turn Mimetics Based on the Hexahydropyrazino[1,2-a]pyrazine-1,2-dione Scaffold
Adam Mieczkowski et al.
SYNTHESIS-STUTTGART (2010)
A traceless solid-supported synthesis of novel pyrazinediazepinedione derivatives
Adam Mieczkowski et al.
TETRAHEDRON (2010)
Structure validation in chemical crystallography
Anthony L. Spek
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2009)
Modulators of arginine metabolism support cancer immunosurveillance
Giusy Capuano et al.
BMC IMMUNOLOGY (2009)
OLEX2: a complete structure solution, refinement and analysis program
Oleg V. Dolomanov et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2009)
Mercury CSD 2.0 -: new features for the visualization and investigation of crystal structures
Clare F. Macrae et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2008)
A short history of SHELX
George M. Sheldrick
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2008)
The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels
Bing Zhu et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Tadalafil pharmacokinetics in healthy subjects
ST Forgue et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation
MA Blount et al.
MOLECULAR PHARMACOLOGY (2004)
Overview of phosphodiesterase 5 inhibition in erectile dysfunction
RC Rosen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
The discovery of tadalafil:: A novel and highly selective PDE5 inhibitor.: 1:: 5,6,11,11a-tetrahydro-1H-imidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues
A Daugan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
The discovery of tadalafil:: A novel and highly selective PDE5 inhibitor.: 2:: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues
A Daugan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Share Paper
